SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels Inc. ($UUUU) is trending amid speculation around upcoming earnings and potential government contracts related to uranium and rare earth elements. Community discussions highlight the stock's volatility, with some traders pointing to unusual options activity and anticipating a significant price movement. Others suggest that any pullback represents a buying opportunity, citing the company's strategic importance in securing domestic supply chains.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

ZVRA is trending as rumors of potential acquisition swirl, with the community buzzing about a potential buyout after reports of a failed financing attempt from a smaller company.  Enthusiasm is building for the upcoming earnings report and the potential for a positive outcome, while some investors express skepticism toward management. Bullish sentiment is further fueled by high short interest, leading to speculation about a possible short squeeze.

NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of neurobehavioral and neurocognitive disorders. Its product portfolio includes Quilience, a treatment for excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol, a treatment for attention deficit hyperactivity disorder. The company was founded by Ronald Hafner, Eric Konofal, and Alexander Zwyer on June 10, 2015 and is headquartered in Zurich, Switzerland.

NewcelX Ltd.

NCEL is trending as investors grapple with the implications of its recent merger and reverse stock split, with some expressing confusion and concern over trading discrepancies and stock valuations. Community discussions revolve around the potential for a short squeeze and the company's future prospects post-merger. The merger with Kadimastem is seen by some as a positive catalyst, while others remain skeptical about the combined entity's valuation and potential.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as investors discuss its high valuation and potential ahead of earnings, with some pointing to strong AI growth and government contracts as reasons for optimism. The community is debating whether the stock can maintain its momentum and if it will beat expectations. Discussions include potential stock splits and comparisons to other high-growth tech companies.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals ($BCRX) is trending as investors anticipate upcoming earnings and key updates on its pipeline, including BCX17725 for Netherton syndrome. Community discussions focus on the potential for a positive conference call with improved guidance, overshadowing concerns about debt and valuation. Optimism surrounds the integration of Astria's assets and potential label expansion for Orladeyo, as analysts project earnings growth.

Space and Time is the Microsoft-backed blockchain for ZK-proven data. Powered by Proof of SQL, a sub-second ZK coprocessor, Space and Time allows smart contracts, AI agents, and onchain applications to query onchain and offchain data at scale and verify the results with cryptographic proofs. The foundation of Space and Time is a decentralized layer 1 blockchain where validators verify every piece of data that gets inserted into the network, updating and signing cryptographic commitments on the data before recording them onchain. Developers can query this data via Proof of SQL and receive back a trustless, tamperproof result onchain. Space and Time allows smart contracts to query over the full history of major blockchains and offchain sources in a verifiable way, enabling a new generation of sophisticated, data-driven onchain apps.  The SXT token is deployed as an ERC-20 token on Ethereum and functions as the network's native utility token. SXT is used for staking, data processing payments, access control, and incentives for data contributors.

Space and Time

Space and Time ($SXT) is trending amid community excitement surrounding its technology and partnerships, particularly with Microsoft and Chainlink. Discussions center on its potential for growth in the AI and decentralized data space, with some highlighting recent integrations and others anticipating a breakout. The community is closely watching for further developments that could drive broader adoption and price appreciation.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

GILD is trending due to recent earnings and analyst upgrades, though the stock's reaction is mixed, with some questioning if investor expectations weren't fully met. Community discussions revolve around the company's HIV and oncology pipeline, potential acquisitions (such as RCUS or XLO), and the impact of regulatory decisions. Several actionable alerts and technical analyses are being shared, with call options being a popular strategy.

United States Commodity Funds LLC - United States Natural Gas Fund

United States Natural Gas Fund, LP

UNG is trending amid speculation around winter weather and potential supply constraints, with some traders anticipating a significant rally. Community discussions revolve around technical indicators, potential breakout levels, and the impact of data center energy consumption on natural gas demand. Despite strong storage levels, expectations of increased demand and potential disruptions are fueling bullish sentiment.

Direxion Shares ETF Trust - Direxion Daily Junior Gold Miners Index Bull 2X Shares

Direxion Daily Junior Gold Miners Index Bull 2X Shares

JNUG is trending due to LiquidTheta's LEAPS options alerts, sparking community interest in potential ROI. Additionally, news of China and Canada expanding trade and energy ties could provide tailwinds. However, concerns about consumer recession, layoffs, and banking stress are also circulating, adding complexity to the discussion around JNUG and junior gold miners.

Peloton Interactive, Inc. provides an at-home fitness platform for live and on-demand indoor cycling classes. The firm pioneered connected, technology-enabled fitness, and the streaming of immersive, instructor-led boutique classes for its members. It operates through the Connected Fitness Products and Subscription segments. The Connected Fitness Products segment includes the sales of bikes, tread & related accessories. The Subscription segment refers to the monthly subscription and credits from live studio classes. The company was founded by John Foley, Graham Stanton, Thomas Cortese, Yony Feng, and Hisao Kushi in 2012 and is headquartered in New York, NY.

Peloton Interactive Inc - Ordinary Shares - Class A

Peloton Interactive Inc

Peloton is trending as the community discusses its potential for a turnaround, fueled by recent analyst upgrades and speculation around new AI-integrated products. Community members are debating whether the stock is poised for a Carvana-like surge, while others caution about the impact of the broader economic environment and short interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AbbVie Q3 Earnings & Sales Beat, 2025 EPS Outlook Raised

ABBV tops Q3 earnings and revenue estimates, driven by Rinvoq and Skyrizi gains, and lifts its 2025 EPS outlook.

ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales

Alnylam's Q3 earnings and revenues surge past forecasts, powered by booming Amvuttra sales and a key milestone payment from Roche.

BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS View

Biogen's Q3 earnings and sales top estimates on strong drug demand, but shares slide after the company cuts its 2025 EPS forecast.

REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase 

Regeneron's Q3 earnings beat forecasts as strong Dupixent profits and rising Eylea HD sales offset a decline in its flagship Eylea brand. 

Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition

Novartis' Q3 profit rose on 8% higher sales led by Kisqali, Kesimpta and Pluvicto, as new acquisitions expand its neuroscience and cardiovascular reach.

Should You Buy AbbVie Stock Ahead of Q3 Earnings Report?

ABBV's Q3 results are likely to hinge on Skyrizi and Rinvoq growth, as Humira erosion and hefty IPR&D charges are expected to pressure near-term earnings.

Is Halozyme Stock a Portfolio Must-Have Ahead of Q3 Earnings?

HALO gears up for third-quarter earnings with strong royalty growth and a new acquisition poised to shape its 2025 outlook.

Will Higher Royalties From Partners Fuel HALO's Growth in H2 2025?

Halozyme boosts its 2025 revenue outlook on surging royalties from Darzalex SC, Phesgo and Vyvgart Hytrulo, though partner reliance persists.

RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised 

Roche's Q3 sales climbed 6% to CHF 14.9B, powered by surging demand for Phesgo, Xolair, Hemlibra, Vabysmo, and Ocrevus.

Roche's Gazyva Secures FDA Nod for Label Expansion in Lupus Nephritis

RHHBY secures FDA approval to expand Gazyva's label for treating lupus nephritis, offering patients a faster and more convenient treatment option.

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics, and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Roche Holding AG - ADR

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$40.40
Prev Close	$40.61
Open	$40.42
Dividend Yield	2.45%
50-Day Moving Average	$42.47
Beta	0.33
Avg. Volume	1.26M
PE Ratio	23.58

52-Week High	$45.94
52-Week Low	$34.10
Market Capitalization	$210.89B
EPS (Annual)	$1.47
Price to Book	7.14
Revenue Per Employee	$665,306.28
Enterprise Value/EBITDA	N/A

RHHBY
Roche Holdings AG ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RHHBY News

RHHBYRoche Holdings AG ADR